2023 World Conference on Lung Cancer (Posters)-EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre

EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre - PDF(Abstract)

Back to course

Pdf Summary

This study presented at the WCLC 2023 conference in South Korea focused on the prevalence and treatment of advanced non-small cell lung cancer (NSCLC) patients with RET fusions. RET fusions occur in 1-2% of NSCLC patients globally and an estimated 1.9-6% of cases in South Korea. The study analyzed data from the Asan Medical Center (AMC) and found that 4.3% of stage IIIB-IV NSCLC patients tested positive for RET fusions. The most common fusion partners were KIF5B and CCDC6. Systemic Anti-Cancer Therapy (SACT) was the most common first treatment for RET fusion-positive patients, followed by SACT in combination with radiotherapy. The majority of stage IV NSCLC patients received platinum-based chemotherapy doublet as their first-line treatment. Treatment through clinical trials and tyrosine kinase inhibitor (TKI) monotherapy were also common treatment options. The study found that the overall survival of RET fusion-positive NSCLC patients was 71% at 60 months. The authors concluded that the prevalence of RET fusions in NSCLC patients in South Korea is higher than the global average but within the range reported in South Korea. The treatment patterns observed in this study, including the use of selective RET inhibitors and enrollment in clinical trials, suggest that targeted therapies are being utilized for RET fusion-positive NSCLC.

Asset Subtitle

Shinkyo Yoon

Meta Tag

Speaker Shinkyo Yoon

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

NSCLC

RET fusions

Asan Medical Center

stage IIIB-IV

KIF5B

CCDC6

Systemic Anti-Cancer Therapy

SACT

clinical trials

targeted therapies